Is oral semaglutide available in the UK now?

Step 1: understand what the MHRA approval actually says

The MHRA's June 2026 decision licences Wegovy tablets for adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol or pre-diabetes. That mirrors the injection's eligibility framework closely.

The dosing ladder runs 1.5mg, then 4mg, then 9mg, then 25mg, a minimum of one month at each level before moving up. Patients already stable on the 2.4mg weekly injection can, in principle, move directly to the 25mg tablet, though a prescriber needs to make that call based on your individual history. For the exact schedule, the MHRA Products website carries the Wegovy tablet SmPC on the eMC, and that's the authoritative source for dosing detail.

Novo Nordisk built an absorption enhancer called SNAC into each tablet, which allows semaglutide to cross the stomach lining rather than being broken down by digestive acid. Without it, oral semaglutide wouldn't work at all. If you're wondering whether semaglutide is available in pill form and how that compares to the injection, the mechanism is the same once it's in your bloodstream (GLP-1 receptor agonism, appetite regulation, slower gastric emptying) and the delivery route is simply different.

One quick habit worth building early: before ordering from any online pharmacy, spend under a minute checking their entry on the GPhC pharmacy register. A legitimate pharmacy has a registration number you can search; if you can't find one, that's your answer.

Step 2: know how trial results differ from the injection's numbers

The phase 3 evidence comes from the OASIS 4 trial, 307 adults with obesity or overweight plus at least one weight-related condition, no diabetes, running for 64 weeks. Average weight loss was around 13.6% compared with roughly 2.4% on placebo. Among participants who stayed fully adherent to treatment throughout, the figure rose to approximately 16.6%.

That's a meaningful distinction. The 13.6% is the population average regardless of how consistently people took the tablet; the higher figure applies only to the fully-adherent group. Both are from the same trial, both are real, but quoting ~17% without that context misrepresents what most people in the study experienced. The MHRA's approval announcement on 11 June 2026 gives the canonical figures.

For comparison, the STEP 1 trial of the 2.4mg weekly injection reported around 15% average weight reduction over 68 weeks, as documented by the NHS semaglutide medicines page. The tablet's average sits slightly below that, though the gap narrows when adherence is strong. Neither figure is a guarantee of what any individual will experience.

Side effects in OASIS 4 were predominantly gastrointestinal (nausea, diarrhoea, constipation, reflux) affecting around 74% of the tablet group versus 42% of the placebo group. Most were mild to moderate and tended to settle as the body adjusted, particularly if the dose escalation was paced carefully. That's consistent with what the injection produces, especially in the early weeks.

Step 3: work out whether the injection or tablet suits your situation better

The injection and tablet treat the same condition via the same biological mechanism. The practical differences are real, though. No needles, no refrigeration, and a daily routine rather than a weekly one, those things matter to plenty of people. Equally, some patients find a once-weekly injection easier to remember than a daily tablet taken under specific conditions.

The tablet has firm requirements: taken first thing in the morning, on a completely empty stomach, with a small amount of plain water (up to around 120ml), then a wait of at least 30 minutes before food, other drinks (including coffee) or any other oral medicines. If your mornings are already structured around those kinds of gaps, it fits naturally. If they're not, it's worth thinking through before committing.

Cost is another factor. If you'd like to compare what private treatment typically costs across the options, the Wegovy tablet pricing page covers what's usually included and what market prices look like. The short version: for a prescription medicine, the question of which option fits your clinical profile should come before the question of which is cheaper.

The oral semaglutide dosing guide has more detail on how the escalation schedule works in practice, and the semaglutide oral tablets page covers the tablet's mechanism and trial data in full.

Step 4: access it through a regulated UK prescription pathway

Wegovy tablets are a prescription-only medicine. There is no legal route to them that bypasses a clinical assessment, and for good reason. A prescriber checks for contraindications, assesses your medical history, and confirms the medicine is appropriate before writing a prescription.

NICE has not yet appraised Wegovy tablets for NHS use, so a NICE appraisal would need to happen before NHS commissioning could follow. If you're uncertain about timing and want to know when the Wegovy pill will be available in the UK more broadly, that page covers the current situation with NHS access and what to expect next. If you're also curious how the injection pathway compares on the NHS side, the weight-loss treatment overview explains what's currently commissioned and what isn't.

At nume, every consultation for Wegovy tablets (as for any prescription weight-loss medicine) is personally reviewed the same day by a GPhC-registered prescriber, not automated software. Our pharmacy holds GPhC registration number 9012878, verifiable at any point on the GPhC register. Treatment is sourced through the licensed UK supply chain and dispatched in plain, unbranded packaging.

If you'd like to find out whether Wegovy tablets are right for your circumstances, speak to our prescribers through a free consultation, there's no commitment and no fee for the assessment itself.